Levetiracetam-induced eosinophilic pneumonia

BMJ Case Rep. 2017 Mar 8:2017:bcr2016219121. doi: 10.1136/bcr-2016-219121.

Abstract

Levetiracetam is widely regarded as a benign antiepileptic drug, compared to older antiepileptic medication. We report a case of eosinophilic pneumonia due to levetiracetam use in a non-smoking woman aged 59 years with no previous respiratory history. Our patient presented with exertional breathlessness and marked desaturation on exertion. She displayed 'reverse bat-wing' infiltrates on her chest radiograph and peripheral eosinophilia on a complete blood count. Her symptoms, radiology and peripheral eosinophilia resolved completely with cessation of levetiracetam and a course of prednisolone. This is the first report of isolated eosinophilic pneumonia due to levetiracetam. Other reports of levetiracetam-induced eosinophilia describe drug rash, eosinophilia and systemic symptoms (DRESS syndrome). Detection of pulmonary drug reactions requires a careful drug history and high index of suspicion. Identifying and reporting a causative agent is crucially important, as cessation of the drug is essential for resolution of the syndrome.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Levetiracetam
  • Middle Aged
  • Piracetam / adverse effects
  • Piracetam / analogs & derivatives*
  • Prednisolone / therapeutic use
  • Pulmonary Eosinophilia / chemically induced
  • Pulmonary Eosinophilia / diagnosis*
  • Pulmonary Eosinophilia / drug therapy*
  • Treatment Outcome

Substances

  • Levetiracetam
  • Prednisolone
  • Piracetam